Manufacturing Deficiencies Delay Decision on Eflapegrastim
Eflapegrastim is a novel, long-acting G-CSF comprised of 2 protein components, an analogue of G-CSF and an Fc antibody fragment.
Hematologic Disorders
Iron Deficiency Anemia Treatments
Recommendations for the management of iron deficiency anemia including oral and intravenous iron therapies.
Thromboembolic Disorders: Treatments
Anticoagulants, antiplatelets, and thrombolytics for the treatment and/or prophylaxis of venous and arterial thrombosis.
FDA-Approved Biosimilars
A comparative list of biosimilars approved by the FDA including their reference products, dosage forms and indications.
Bleeding Disorder Treatments: Hemophilia A
Treatment options for Hemophilia A including factors and other biologics.
Highlights of the 2021 Joint Guidelines for Managing von Willebrand Disease
These guidelines from ASH, ISTH, NHF, and WFH are intended to support patients, clinicians, and healthcare professionals in their decisions affecting the management of VWD.
FDA Issues Guidance on Coagulation Systems to Measure Viscoelasticity During COVID-19 Pandemic
The FDA has issued guidance to facilitate the availability of coagulation systems during the COVID-19 pandemic.
Assessing Variations in Hematopoietic Stem Cell Transplant Referral Patterns for Children With Sickle Cell Disease
Investigators noted the importance of improving educational efforts about the safety and efficacy of matched sibling donor HSCT for children with sickle cell disease.
Narsoplimab Under Review for Stem Cell Transplant-Associated Thrombotic Microangiopathy
The FDA has accepted for filing and granted Priority Review to narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
- Loading...
Loading...
Next post in Hematopoietic Stem Cell Transplantation
Loading... 
Loading...